Serial No.: 09/155,642 Filed: October 2, 1998

Page -2-

Docket No.: <u>28069-541 NATL</u> (Formerly: 402090/SkyePharma)

## **Listing of Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

## 1-54. (Canceled)

- 55. (Currently amended) A solid[,] dermatological composition comprising a biologically active agent dissolved in a homogeneous carrier system, wherein the carrier system includes consists essentially of:
- (a) 20-85% by weight of a solvent comprising (i) an unsaturated C<sub>16</sub>-C<sub>20</sub>-fatty acid alcohol selected from one or more of oleyl alcohol, ricinolyl alcohol, linolyl alcohol, linolyl alcohol, linolyl alcohol, linolyl alcohol, eleosteryl alcohol, palmitoleyl alcohol, or arachidonyl alcohol in combination with (ii) an alkylene glycol selected from one or more of propylene glycol or dipropylene glycol, said alkylene glycol being present in the solvent in an amount of more than 12% by weight to provide for mutual dissolution of the unsaturated C<sub>16</sub>-C<sub>20</sub>-fatty acid alcohol and the active agent; and

a solvent for said active agent, comprising 20 to 85% by weight of an unsaturated fatty acid alcohol in combination with an alkylene glycol, said fatty acid alcohol being selected from oleyl alcohol, ricinolyl alcohol, linolyl alcohol and/or linoleyl alcohol, and said alkeylene alkylene glycol being selected from propylene glycol and/or dipropylene glycol, said alkylene glycol being present in an amount of more than 12% by weight to provide for mutual dissolution of said active agent;

- (b) <u>15-80% of a viscosity enhancing agent that is a waxy substance</u> for imparting a solid consistency to the composition <del>15 to 55% by weight of a waxy substance; and</del>
- (c) a plasticizing agent which comprises 2 to 30% by weight of a plasticizing oil; all percentages in (a) and (b) being based on the total weight of the homogeneous carrier system.
- 56. (Currently amended) [A] <u>The composition according to as claimed in claim 55</u>, wherein the amount of said alkylene glycol is at least 15 % by weight.
- 57. (Currently amended) [A] <u>The</u> composition <u>according to</u> as claimed in claim 55, wherein the biologically active agent comprises a lipophilic compound.

Serial No.: 09/155,642 Filed: October 2, 1998

Page -3-

Docket No.: <u>28069-541 NATL</u> (Formerly: 402090/SkyePharma)

- 58. (Currently amended) [A] <u>The</u> composition <u>according to as claimed in claim 57</u>, wherein the biologically active compound is selected from the group consisting of steroids, sex hormones, vitamins, biologically active lipids, fatty acids, antivirals, antibacterials, antiprotozoals, and antifungals, and local anesthetics.
- 59. (Withdrawn) A composition as claimed in claim 58, wherein the biologically active compound is selected from fluorinonide, omega-3-fatty acid and azelaic acid and salts and esters thereof.
- 60. (Withdrawn) A composition as claimed in claim 58, wherein the biologically active compound is clobetasol or a salt or an ester thereof.
- 61. (Currently amended) [A] <u>The composition according to as claimed in claim 55</u>, wherein the alkylene glycol is propylene glycol.
- 62. (Currently amended) [A] <u>The composition according to as claimed in claim 55</u>, wherein the solvent additionally comprises propyl myristate, palmitate, <u>isopropylpalmitate</u>, <u>and/or stearate</u>, <u>and/or propyl ester of sorbic acid and combinations thereof</u>.
- 63. (Currently amended) [A] <u>The</u> composition <u>according to</u> as claimed in claim 62, wherein said additional solvent is isopropylpalmitate.
- 64. (Currently amended) [A] <u>The</u> composition <u>according to</u> as claimed in claim 55, wherein the waxy substance comprises a natural <del>and/</del>or synthetic wax[;], a fat[;], a glycol ester of a C<sub>18</sub>-C<sub>36</sub> fatty acid[;], or a mixture of two or more <u>such compounds</u> thereof.
- 65. (Currently amended) [A] <u>The</u> composition <u>according to</u> as claimed in claim 64, wherein the waxy substance comprises a combination of a natural or synthetic wax and <u>one or</u> a combination of a triglyceride or a glycol ester. a triglyceride and/or a glycol ester.

66.-67. (Canceled)

68. (Currently amended) [A] <u>The composition according to as claimed in claim 55</u>, wherein the amount of solvent is within the range of 25-75 % by weight, <u>and the amount of</u>

Serial No.: 09/155,642 Filed: October 2, 1998

Page -4-

Docket No.: 28069-541 NATL (Formerly: 402090/SkyePharma)

viscosity enhancing agent is within the range of 15-55%, based on the total weight of the homogeneous carrier system.

- 69. (Currently amended) [A] <u>The</u> composition <u>according to as claimed in claim 55</u>, wherein the amount of said alkylene glycol is within the range of 12-23% by weight, <u>based on</u> the total weight of the homogeneous carrier system.
- 70. (Currently amended) [A] <u>The</u> composition <u>according to</u> <u>as claimed in</u> claim 62, wherein the weight ratio of unsaturated fatty acid: alcohol additional solvent ranges from 1:2 to 5:1.
- 71. (Currently amended) [A] <u>The</u> composition <u>according to</u> <u>as claimed in</u> claim 55, wherein the biologically active agent is present in a concentration of up to the solubility limit thereof in the <u>homogeneous</u> carrier system.
- 72. (Currently amended) [A] <u>The composition according to as claimed in claim 55</u>, wherein the concentration of the biologically active agent is 0.01-10%, by weight, based on the weight of the homogeneous carrier system.
- 73. (Currently amended) [A] <u>The composition according to as claimed in claim 55</u>, wherein said composition is a stick.
- 74. (Currently amended) [A] <u>The</u> composition <u>according to</u> as claimed in claim 55, wherein said the biologically active agent is a therapeutically or prophylactically active agent.
- 75. (Currently amended) [A] <u>The composition according to as claimed in claim 74</u>, for topical application to the skin of a mammal, <u>and possesses a said</u> composition [has] <u>having a viscosity that is adapted for such said application.</u>
- 76. (Currently amended) A process for the preparation of a biologically active composition as claimed in according to claim 55, comprising: dissolving the biologically active agent in said solvent therefore[,]; combining the resulting solution with a viscosity enhancing agent and the plasticizing agent so as to impart a solid consistency to said solution; and shaping the resulting composition into a desired form.

Applicants: Ake LINDAHL, et al.

Serial No.: 09/155,642

Docket No.: 28069-541 NATL

(Formerly: 402090/SkyePharma)

Serial No.: 09/155,642 Filed: October 2, 1998

Page -5-

77. (Currently amended) A method of prophylactic or therapeutic treatment of a dermatological condition comprising: topically applying a prophylactically or therapeutically effective amount of an active agent containing the solid composition according to claim 55, wherein the active agent is an agent for treatment or prophylaxis of a dermatological condition.

- 78. (Currently amended) The method [of] <u>according to</u> claim 77, wherein the active agent is selected from the group consisting of a steroid, vitamin, biologically active lipid, fatty acid, antimicrobial, and anesthetic.
- 79. (Currently amended) The method [of] according to claim 77, wherein the active agent is selected from the group consisting of a corticosteroid, sex hormone, vitamin A, vitamin B2, vitamin B3, vitamin E, vitamin K, an antibiotic, an antiviral, an anti-protozoal, an antifungal, and an amide local anesthetic.
- 80. (Withdrawn) The method of claim 77, wherein the active agent is selected from the group consisting of clobetasol, or a salt or ether thereof and beta-methasone, or a salt or ester thereof.
- 81. (Withdrawn) The method of claim 80, wherein the active agent is clobetasol proprionate, methasone-17-valerate, or beta-methasone diproprionate.
- 82. (Currently amended) [A] <u>The</u> composition <u>according to</u> as claimed in claim 55, wherein the biologically active agent is a lipophilic drug.
- 83. (Withdrawn) A composition as claimed in claim 57, wherein the biologically active compound is a lipophilic anesthetic of the amide type.
- 84. (Withdrawn) A composition as claimed in claim 60, wherein the biologically active compound is clobetasol propionate.
- 85. (Currently amended) [A] <u>The</u> composition <u>according to</u> <u>as claimed in claim 60 55</u>, wherein the waxy substance comprises a natural <u>and/or or a</u> synthetic wax that is a monoester of a long-chain carboxylic acid with a long-chain alcohol, and the fat is a triglyceride of a C<sub>18</sub>-C<sub>36</sub> fatty acid.

Serial No.: 09/155,642 Filed: October 2, 1998

Page -6-

١,

86.-88. (Canceled)

89. (Currently amended) [A] <u>The composition according to as claimed in claim 55</u>, wherein the amount of said alkylene glycol ranges from 15-23% by weight, based on the total weight of the homogeneous carrier system.

- 90. (Currently amended) [A] <u>The</u> composition <u>according to as claimed in claim 55</u>, wherein the amount of said alkylene glycol ranges from 12-20% by weight, <u>based on the total</u> weight of the homogeneous <u>carrier system</u>.
- 91. (Currently amended) [A] <u>The</u> composition <u>according to</u> <u>as claimed in</u> claim 55, wherein the amount of said alkylene glycol ranges from ranges from 15-20% by weight, <u>based</u> on the total weight of the homogeneous <u>carrier system</u>.
- 92. (Currently amended) [A] <u>The</u> composition <u>according to</u> <u>as claimed in</u> claim 62, wherein the weight ratio of unsaturated fatty acid alcohol: additional solvent is within the range of 1:2 to 3:1.
- 93. (Currently amended) [A] <u>The</u> composition <u>according to</u> as claimed in claim 62, wherein the weight ratio of unsaturated fatty acid alcohol: additional solvent is within the range of 1:2 to 2:1.
- 94. (Currently amended) [A] <u>The composition according to as claimed in claim 55</u>, wherein the concentration of the biologically active agent is 0.02-5% by weight based on the weight of the <u>homogeneous</u> carrier system.
- 95. (Withdrawn) A composition as claimed in claim 55, wherein the biologically active compound is betamethasone, or a salt or ester thereof.
- 96. (Withdrawn) A composition according to claim 55, wherein the biologically active compound is beta-methasone-17-valerate or beta-methasone diproprionate.
- 97. (Currently amended) [A] <u>The</u> composition <u>according to</u> of claim 58, wherein the steroid is a corticosteroid.

Express Mail Label No.: EV 627295415US

Docket No.: 28069-541 NATL

(Formerly: 402090/SkyePharma)

Serial No.: 09/155,642 Filed: October 2, 1998

Page -7-

Docket No.: <u>28069-541 NATL</u> (Formerly: 402090/SkyePharma)

- 98. (Withdrawn) The compound of claim 58, wherein the sex hormone is selected from the group consisting of androgens, estrogens and derivatives thereof.
- 99. (Withdrawn) The compound of claim 58, wherein the vitamin is selected from the group consisting of vitamin A, vitamin B2, vitamin B3, vitamin E and vitamin K.